FXR, a nuclear receptor expressed in the liver and intestine, is a key regulator of bile acid, inflammatory, fibrotic and metabolic pathways.
In addition to their role in digestion and absorption, bile acids have been shown to bind and activate dedicated receptors like FXR.
Intercept's lead compound, obeticholic acid (OCA), is an analog of the bile acid chenodeoxycholic acid (CDCA).
FXR biology is at the core of our therapeutic research. This treatment modality has applications for PBC, and potentially other liver conditions such as NASH.